Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XMT-1107
- Development stage
- Phase 1
- Lead developer
- Mersana Therapeutics
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
XMT-1107 is a polymer-drug conjugate consisting of a small molecule fumagillol derivative (XMT-1191) chemically tethered to Fleximer, a 70 kDa biodegradable and hydrophilic polymer. This design improves solubility and extends the half-life of the active agent compared to unconjugated analogs. XMT-1107 acts as an inhibitor of methionine aminopeptidase 2 (MetAP2), an enzyme involved in angiogenesis, thereby exerting anti-tumor effects by blocking the growth of new blood vessels that support tumor survival. The Fleximer backbone prevents crossing of the blood-brain barrier, potentially reducing central nervous system toxicity seen with earlier agents in this class. XMT-1107 was developed for use as an anti-cancer agent, particularly for advanced solid tumors[1][2][3][4][5].
- Other names
- fumagillin-derived polymer conjugate xmt-1107
02
Targets
METAP2 (Methionine aminopeptidase 2)
Beyond the preview
Go deeper on XMT-1107.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XMT-1107.